X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (659) 659
Publication (107) 107
Book Review (7) 7
Newsletter (7) 7
Magazine Article (3) 3
Book Chapter (2) 2
Conference Proceeding (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (637) 637
hiv infections - drug therapy (528) 528
raltegravir potassium (494) 494
index medicus (438) 438
pyrrolidinones - therapeutic use (337) 337
male (314) 314
female (308) 308
raltegravir (280) 280
infectious diseases (271) 271
adult (267) 267
anti-hiv agents - therapeutic use (263) 263
middle aged (232) 232
hiv integrase inhibitors - therapeutic use (225) 225
hiv infections - virology (220) 220
hiv (192) 192
hiv-1 - drug effects (187) 187
pharmacology & pharmacy (178) 178
viral load (159) 159
immunology (152) 152
treatment outcome (146) 146
antiviral agents (138) 138
antiretroviral therapy (133) 133
raltegravir potassium - therapeutic use (124) 124
drug therapy, combination (116) 116
microbiology (113) 113
virology (109) 109
cd4 lymphocyte count (107) 107
hiv infection (104) 104
pyrrolidinones - adverse effects (102) 102
pyrrolidinones - pharmacology (102) 102
hiv-1 - genetics (98) 98
drug resistance, viral (94) 94
hiv-1 (94) 94
drug therapy (90) 90
safety (90) 90
efficacy (88) 88
infection (86) 86
pyrrolidinones - administration & dosage (86) 86
hiv integrase inhibitors - pharmacology (84) 84
anti-hiv agents - adverse effects (83) 83
human immunodeficiency virus--hiv (83) 83
hiv integrase inhibitors - adverse effects (82) 82
aids/hiv (78) 78
anti-hiv agents - administration & dosage (78) 78
pharmacokinetics (75) 75
therapy (72) 72
dosage and administration (71) 71
rna, viral - blood (70) 70
aids (68) 68
anti-hiv agents - pharmacology (68) 68
integrase (68) 68
pyrrolidinones (68) 68
drug interactions (67) 67
antiretroviral therapy, highly active (66) 66
analysis (65) 65
antiretroviral drugs (64) 64
pyrrolidinones - pharmacokinetics (64) 64
hiv integrase - genetics (63) 63
mutation (63) 63
young adult (63) 63
protease inhibitors (62) 62
care and treatment (61) 61
integrase inhibitor (61) 61
ritonavir - therapeutic use (61) 61
hiv integrase inhibitors - administration & dosage (60) 60
research (59) 59
hiv protease inhibitors - therapeutic use (58) 58
double-blind (57) 57
hiv infections - immunology (55) 55
combination therapy (54) 54
health aspects (54) 54
organic chemicals - therapeutic use (54) 54
tenofovir (54) 54
hiv integrase inhibitors - pharmacokinetics (52) 52
darunavir (51) 51
drug resistance (50) 50
reverse transcriptase inhibitors - therapeutic use (50) 50
hiv-1 - isolation & purification (49) 49
aged (47) 47
drug resistance, viral - genetics (47) 47
highly active antiretroviral therapy (47) 47
retrospective studies (47) 47
resistance (46) 46
antiretroviral therapy, highly active - methods (45) 45
adolescent (44) 44
genotype (44) 44
hiv-infected patients (44) 44
mk-0518 (44) 44
viral load - drug effects (44) 44
adenine - analogs & derivatives (43) 43
human immunodeficiency virus (43) 43
integrase inhibitor raltegravir (43) 43
integrase inhibitors (43) 43
treatment-experienced patients (43) 43
hiv infections - complications (42) 42
article (41) 41
drug administration schedule (41) 41
clinical trials as topic (40) 40
cyclohexanes - therapeutic use (40) 40
medicine (40) 40
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (630) 630
Spanish (19) 19
German (14) 14
French (3) 3
Japanese (2) 2
Russian (2) 2
Chinese (1) 1
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Infectious Diseases, ISSN 0022-1899, 10/2015, Volume 212, Issue 8, pp. 1241 - 1249
Background. Specific antiretroviral therapy (ART) medications and the severity of human immunodeficiency virus (HIV) disease before treatment contribute to... 
human immunodeficiency virus | bone mineral density | protease inhibitor | inflammation | integrase inhibitor | INTIMA-MEDIA THICKNESS | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | TURNOVER | EMTRICITABINE | MICROBIOLOGY | OSTEOPROTEGERIN | IMMUNOLOGY | HIV-INFECTED ADULTS | PROTEASE INHIBITORS | THERAPY | RECEPTOR ACTIVATOR | Raltegravir Potassium - adverse effects | Humans | Middle Aged | Raltegravir Potassium - therapeutic use | Male | Atazanavir Sulfate - adverse effects | HIV - drug effects | Viral Load | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | HIV Protease Inhibitors - adverse effects | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | HIV Protease Inhibitors - therapeutic use | Atazanavir Sulfate - therapeutic use | Bone Density - drug effects | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Darunavir - adverse effects | HIV Infections - physiopathology | Darunavir - therapeutic use | Antiviral agents | Care and treatment | Analysis | Bones | Dosage and administration | Inflammation | HIV infection | Density | Risk factors | Major and Brief Reports
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 06/2015, Volume 60, Issue 12, pp. 1842 - 1851
Journal Article
Journal Article
Journal Article
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 01/2017, Volume 56, Issue 1, pp. 25 - 40
Journal Article
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2015, Volume 61, Issue 5, pp. 809 - 816
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2017, Volume 64, Issue 11, pp. 1591 - 1596
Background. The long-term effectiveness of human immunodeficiency virus (HIV) treatments containing integrase inhibitors is unknown. Methods. We use... 
Comparative effectiveness | HIV | Cohort study | Mortality | Raltegravir | INFECTIOUS DISEASES | cohort study | EFFICACY | SAFETY | HIV-1 INFECTION ANALYSIS | raltegravir | MARGINAL STRUCTURAL MODELS | MICROBIOLOGY | ANTIRETROVIRAL THERAPY | IMMUNOLOGY | TRIAL | NAIVE PATIENTS | comparative effectiveness | mortality | DOUBLE-BLIND | Raltegravir Potassium - adverse effects | United States - epidemiology | HIV Infections - epidemiology | Humans | Middle Aged | Raltegravir Potassium - administration & dosage | Raltegravir Potassium - therapeutic use | Male | RNA, Viral - blood | Tenofovir - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - mortality | Reverse Transcriptase Inhibitors - therapeutic use | Tenofovir - adverse effects | Benzoxazines - administration & dosage | Tenofovir - therapeutic use | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | CD4 Lymphocyte Count | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | HIV Integrase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - epidemiology | Acquired Immunodeficiency Syndrome - mortality | HIV Infections - drug therapy | Viral Load - drug effects | Cohort Studies | HIV patients | Care and treatment | Dosage and administration | Efavirenz | HIV infection | Major
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 12/2015, Volume 59, Issue 12, pp. 7903 - 7905
Journal Article